Bicara Therapeutics Inc. stock analysis
Want to see BCAX full AI Analyst Report?
Bicara Therapeutics Inc. (BCAX) Stock Price & Analysis
BCAX Stock Chart & Stats
- Day’s Range
- $9.34 - $9.92
- 52-Week Range
- $7.87 - $30.99
- Previous Close
- $9.75
- Volume
- N/A
- Average Volume (3M)
- 1.81M
- Market Cap
- $647.28M
- Enterprise Value
- $831.00M
- Total Cash (Recent Filing)
- $442.35M
- Total Debt (Recent Filing)
- $880.00K
- Price to Earnings (P/E)
- ―
- Beta
- 1.71
- Next Earnings
- Apr 01, 2027 (Est.)
- EPS Estimate
- -1.04
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Durable Clinical Efficacy
The reported Phase Ib responses are both deep and durable, with substantial tumor shrinkage and nearly two years of median response duration. If confirmed in the pivotal program, this profile could support meaningful differentiation in HPV-negative head and neck cancer and strengthen the candidate’s clinical positioning.
Pivotal Trial Advancement
Substantial enrollment in the approximately 650-patient pivotal study indicates meaningful clinical execution and moves the program toward an important efficacy readout. The planned interim analysis should provide a more consequential test of whether earlier clinical signals can translate into regulatory and commercial progress.
Funding Runway And Low Leverage
A cash runway extending into the first half of 2029 gives Bicara time to advance its pivotal study, regulatory preparation, manufacturing, and early commercial infrastructure. Minimal debt further reduces fixed financing pressure while the company remains dependent on clinical development rather than product revenue.
Bears Say
Pre-Revenue Loss Profile
Without product revenue, Bicara’s financial performance is determined by research, development, and organizational spending rather than commercial execution. Losses have widened sharply over time, increasing the distance to self-funded operations and making future value increasingly dependent on successful clinical and regulatory outcomes.
Accelerating Cash Burn
The worsening operating and free cash flow profile shows that advancing the pipeline requires substantial ongoing funding. Persistent burn can reduce financial flexibility before revenue begins and may create future reliance on equity financing or other capital, with potential dilution if spending remains elevated.
Pivotal And Regulatory Uncertainty
The pivotal study has not yet produced definitive data, while the filing path and interim overall survival requirements remain uncertain. These unresolved clinical and regulatory questions can delay approval, require additional evidence, or weaken the ability to convert promising Phase Ib results into a reliable development timeline.
Bicara Therapeutics Inc. News
Analyst Reaffirms Buy on Bicara, Citing Ficera’s Differentiated Efficacy and Chemo-Free Profile; Price Target Maintained at $34
Bank of America Securities analyst Tazeen Ahmad maintained a Buy rating on Bicara Therapeutics Inc. today and set a price target of $34.00. Tazeen Ahmad has given his Buy rating
BCAX FAQ
What was Bicara Therapeutics Inc.’s price range in the past 12 months?
What is Bicara Therapeutics Inc.’s market cap?
When is Bicara Therapeutics Inc.’s upcoming earnings report date?
How were Bicara Therapeutics Inc.’s earnings last quarter?
Is Bicara Therapeutics Inc. overvalued?
Does Bicara Therapeutics Inc. pay dividends?
What is Bicara Therapeutics Inc.’s EPS estimate?
How many shares outstanding does Bicara Therapeutics Inc. have?
What happened to Bicara Therapeutics Inc.’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Bicara Therapeutics Inc.?
What is the TipRanks Smart Score and how is it calculated?
Bicara Therapeutics Inc. Stock Smart Score
Company Description
Bicara Therapeutics Inc.
Bicara Therapeutics Inc., a biopharmaceutical firm in the clinical development phase, is headquartered in Boston, Massachusetts. Established in 2018, the company specializes in creating innovative, dual-action treatments specifically for solid tumors. At the forefront of their pipeline is ficerafusp alfa, a unique antibody designed to tackle solid cancers. This bifunctional therapeutic agent works by simultaneously engaging the epidermal growth factor receptor (EGFR) and binding to human transforming growth factor beta (TGF-b). Bicara Therapeutics operates as a subsidiary of Biocon Limited.
- Sector
- General
- Industry
- Biotechnology
- CEO
- Claire Mazumdar Clemon
- Employees
- 103
- Website
- www.bicara.com
- Address
- 116 Huntington Avenue, Boston, MA, 02116, US
Bicara Therapeutics Inc. (BCAX) Earnings & Revenues
BCAX Company Deck
BCAX Earnings Call
Earnings Call SentimentPositive
The call was predominantly positive, driven by substantial pivotal-trial enrollment, plans for an interim overall survival analysis, encouraging and durable Phase Ib efficacy data, Breakthrough Therapy designation, commercial preparation, and a cash runway into the first half of 2029. The main negatives were sharply higher operating expenses, the absence of pivotal data to date, pending regulatory clarity, a competitive market, and the still-early, late-line status of the colorectal cancer program.
View all BCAX earnings summariesBCAX Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 2 | 6 | 14 |
| Technical Analysis | 1 | 6 | 3 |
| Moving Averages | 1 | 0 | 11 |









